Meta Information
ID:mots-c
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/class/antidiabetic-medications
Target name:
Diabetes Medications
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
MOTS-c improves insulin sensitivity and glucose uptake, which can amplify the effects of diabetes medications (e.g., insulin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors), significantly increasing the risk of dangerously low blood sugar (hypoglycemia).
Actionable advice:
Use with extreme caution and under strict medical supervision; dose adjustments of diabetes medications may be required.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The safety of MOTS-c during pregnancy has not been established. Due to its fundamental effects on cellular metabolism, its use is contraindicated as the impact on fetal development is unknown.
Actionable advice:
Avoid completely if you are pregnant.
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is unknown if MOTS-c is excreted in breast milk or what its effects on a nursing infant might be. Its use is contraindicated while breastfeeding.
Actionable advice:
Avoid completely if you are breastfeeding.
Target id:
/condition/active-cancer
Target name:
Active Cancer
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
MOTS-c modulates core metabolic pathways, including folate metabolism, which could unpredictably alter cancer cell growth and proliferation. Its use in patients with active cancer is not studied and is contraindicated.
Actionable advice:
Do not use if you have a current diagnosis of cancer.
Target id:
/intervention/methotrexate
Target name:
Methotrexate
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
MOTS-c regulates the folate-one-carbon metabolism pathway, which is the direct target of the antifolate drug methotrexate. Co-administration could lead to unpredictable and severe cellular toxicity.
Actionable advice:
Avoid completely while taking methotrexate.
Target id:
/intervention/exercise
Target name:
Exercise
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
null
Description:
MOTS-c may prime skeletal muscle for enhanced glucose uptake and mitochondrial activity, potentially improving exercise performance, endurance, and metabolic response.
Actionable advice:
Administer approximately 30-60 minutes before a workout to maximize potential synergistic effects.
Target id:
/class/ampk-activators
Target name:
AMPK Activators (e.g., Metformin, Berberine)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
MOTS-c activates the AMPK pathway, similar to metformin and berberine. Combining these agents can lead to additive effects on glucose metabolism and cellular energy sensing.
Actionable advice:
Be aware of potential additive effects; monitor blood glucose closely when combining with other AMPK activators.
Target id:
/biomarker/folate-b12-status
Target name:
Folate (B9) and Vitamin B12 Status
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Optimal function of MOTS-c depends on the folate-one-carbon metabolism cycle, for which folate and vitamin B12 are essential cofactors. Deficiency may impair its efficacy.
Actionable advice:
Ensure adequate folate and vitamin B12 levels are maintained through diet or supplementation.
Target id:
/biomarker/cgm-glucose-levels
Target name:
Blood Glucose Levels
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Due to its potent effects on glucose metabolism, regular monitoring of blood glucose is crucial to ensure safety and track efficacy, especially when combined with diet, exercise, or other medications.
Actionable advice:
Regularly monitor blood glucose, ideally with a CGM, to track response and prevent hypoglycemia.
Target id:
/dietary/meal
Target name:
Any Caloric Meal
Severity:
minor
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
0.5
Description:
Administering MOTS-c in a fasted state aligns with its mechanism of activating energy-sensing pathways like AMPK, potentially enhancing its metabolic benefits. Food intake may blunt this effect.
Actionable advice:
Take on an empty stomach, at least 2 hours after your last meal and 30 minutes before your next.
Target id:
/circadian/wake
Target name:
Waking Up
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
null
Hours after target:
1
Description:
Endogenous MOTS-c levels exhibit a circadian rhythm. Administering it in the morning may better synchronize with the body's natural metabolic clock.
Actionable advice:
Administer in the morning shortly after waking to align with natural circadian rhythms.
Target id:
/intervention/ss-31
Target name:
SS-31 (Elamipretide)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Both MOTS-c and SS-31 are peptides that enhance mitochondrial function, though through different mechanisms. Their combination is theoretical but may provide complementary benefits for mitochondrial health.
Actionable advice:
This combination is theoretical and should be approached with caution, as clinical data is lacking.